EZH2 and breast cancer: Previous studies showed that EZH2 is frequently expressed in 75.7% of inflammatory BCs and associated with unfavorable prognostic factors including larger size, high histological grade, increased risk for distant metastasis, and first degree family history of BC (25, 26).